New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
11:06 EDTENDP, PLDLFEndo completes acquisition of Paladin Labs
Endo International (ENDP) announced that it has completed the acquisition of Paladin Labs (PLDLF) in a stock and cash transaction currently valued at approximately $2.7B. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe. In connection with the acquisition, Endo and Paladin Labs have been combined under a new company incorporated in Ireland named Endo International. Shares of Endo International will trade on NASDAQ under the ticker symbol ENDP and the Toronto Stock Exchange under the ticker symbol ENL. Under the terms of the transaction, Paladin Labs shareholders received 1.6331 shares of Endo International stock and C$1.16 in cash for each Paladin Labs share they owned upon closing. In addition, for each Paladin Labs share owned at closing, shareholders of Paladin Labs received one share of Knight Therapeutics a newly formed Canadian company that has been separated as part of the transaction. Shareholders of Endo Health Solutions received one share of Endo International for each share of Endo Health Solutions they owned upon closing.
News For ENDP;PLDLF From The Last 14 Days
Check below for free stories on ENDP;PLDLF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
07:46 EDTENDPEndo valuation attractive, says Goldman
Subscribe for More Information
August 8, 2014
09:00 EDTENDPBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use